Japan's PMDA Approves Natera's Signatera as Companion Diagnostic in Muscle-Invasive Bladder Cancer
核心洞察
Japan's PMDA has approved Natera's Signatera (搜索) test as a companion diagnostic to guide adjuvant atezolizumab decisions in muscle-invasive bladder cancer (搜索).
The approval was supported by the randomized, double-blind phase III IMvigor011 trial, which included more than 20 participating sites in Japan.
It is Signatera (搜索)'s second PMDA authorization in three months, following colorectal cancer approval in June 2026, and the first PMDA-approved CDx in MRD-guided care.
Natera, Inc. announced that its Signatera (搜索) test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (搜索) (PMDA) as a companion diagnostic (CDx) in muscle-invasive bladder cancer (搜索) (MIBC). The approval supports the use of Signatera to guide adjuvant atezolizumab (Tecentriq) treatment decisions in patients with MIBC.
Natera expects to commercially launch Signatera (搜索) for MIBC in Japan in the first half of 2027, following the PMDA's approval of atezolizumab in MIBC. The launch remains subject to final reimbursement and pricing.
Trial Basis and Japanese Site Participation
Regulatory approval was supported by data from IMvigor011, a randomized, double-blind phase III clinical trial that evaluated Signatera (搜索)-guided adjuvant atezolizumab in patients with MIBC. The trial included more than 20 participating sites in Japan, which Natera said gave Japanese clinicians firsthand experience with Signatera-guided treatment in this setting.
The company described the authorization as the first PMDA-approved CDx in MRD-guided care. It is Signatera (搜索)'s second PMDA authorization in Japan, following approval in colorectal cancer in June 2026.
Regulatory and Guideline Precedents
The Japanese decision follows the U.S. Food and Drug Administration's approval of Signatera (搜索) as a CDx for adjuvant atezolizumab in MIBC, along with the FDA's approval of atezolizumab in the indication. Natera also cited the recently published Category 1 recommendation for MRD-guided adjuvant atezolizumab in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Bladder Cancer.
"We look forward to launching this second Signatera (搜索) MRD indication in Japan, giving patients with muscle-invasive bladder cancer (搜索) a proven diagnostic tool to guide treatment decisions in the first year after surgery," said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. "We value our growing partnership with the Japanese oncology community, which has been a leader in adopting MRD into clinical trials and into clinical practice."
Disease Burden in Japan
Bladder cancer affects more than 34,000 people in Japan each year, with approximately 20 to 25 percent of newly diagnosed cases classified as muscle-invasive. Natera noted that MIBC carries a higher risk of recurrence and greater treatment complexity than earlier-stage disease, underscoring the need for precision tools that can help clinicians individualize treatment decisions in the adjuvant setting.
Test Platform
Natera positions itself as a global leader in cell-free DNA and precision medicine, with programs in oncology, women's health and organ health. The company states that its tests are supported by more than 400 peer-reviewed publications. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through its subsidiary Foresight Diagnostics (搜索) operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado.
Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.